"Clinical studies [...] have continued to show the ability of daratumumab-based combination treatment regimens to significantly reduce the risk of progression in patients with multiple myeloma," said the study's principal investigator, Meletios A. Dimopoulos, MD, chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine in Greece, in a statement.

Read more...